Dr. Daniel H. Barnett
Claim this profileCarle Cancer Center
Studies Cancer
Studies Tumors
11 reported clinical trials
40 drugs studied
Area of expertise
1Cancer
Stage IV
Stage I
Stage II
2Tumors
Stage IV
Affiliated Hospitals
Clinical Trials Daniel H. Barnett is currently running
Surgery and Radiation vs. Radiation Alone
for Brain Cancer
This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.
Recruiting2 awards Phase 3
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting1 award Phase 221 criteria
More about Daniel H. Barnett
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Daniel H. Barnett has experience with
- Pembrolizumab
- Stereotactic Ablative Radiotherapy
- Radiation Therapy
- Axitinib
- Cabozantinib
- Lenvatinib
Breakdown of trials Daniel H. Barnett has run
Cancer
Tumors
Renal Cell Carcinoma
Kidney Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel H. Barnett specialize in?
Daniel H. Barnett focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage I.
Is Daniel H. Barnett currently recruiting for clinical trials?
Yes, Daniel H. Barnett is currently recruiting for 7 clinical trials in Urbana Illinois. If you're interested in participating, you should apply.
Are there any treatments that Daniel H. Barnett has studied deeply?
Yes, Daniel H. Barnett has studied treatments such as Pembrolizumab, Stereotactic Ablative Radiotherapy, Radiation Therapy.
What is the best way to schedule an appointment with Daniel H. Barnett?
Apply for one of the trials that Daniel H. Barnett is conducting.
What is the office address of Daniel H. Barnett?
The office of Daniel H. Barnett is located at: Carle Cancer Center, Urbana, Illinois 61801 United States. This is the address for their practice at the Carle Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.